List of Vendor Companies in Japan - 20

Pharmaceuticals, diagnostic reagents, medical devices

Providing high-sensitivity quantification services for ultra-trace proteins, we will support research and development of pharmaceuticals, quasi-drugs, reagents, etc.

ちとせグループは、世界のバイオエコノミーをリードするバイオ企業群です。 千年先まで人類が豊かに暮らせる環境を残すべく国や多くの企業と協力し、経済合理性を成立させながら技術を社会に展開しています。 *English follows Japanese. ○ちとせグループ全体を統括する企業 [CHITOSE BIO EVOLUTION PTE. LTD.] ・設立 ：2011年10月 ・本社 ：シンガポール ・代表者 ：CEO 藤田朋宏 Ph.D. ○ちとせグループの中核法人として、技術開発・事業開発を行う企業 [株式会社ちとせ研究所] ・設立 ：2002年11月 ・本社 ：神奈川県川崎市 ・代表者 ：代表取締役 CEO 藤田朋宏 Ph.D.／代表取締役 COO 釘宮理恵 ○プロジェクト例 ・化石資源依存からの脱却！藻類産業を構築するプロジェクト 日: https://matsuri.chitose-bio.com/ 英: https://matsuri.chitose-bio.com/en ・バイオ薬品製造プロセスのスピードアップと低コスト化を実現するプロジェクト 英：https://chitose-bio.com/cld-service 日：https://chitose-bio.com/jp/cld-service ・千年先まで美味しい農作物を提供！健全な土壌環境を重視した農業を普及するプロジェクト 英：https://agriculture.chitose-bio.com/en 日：https://agriculture.chitose-bio.com/ja CHITOSE Group is a family of biotechnology companies leading the global bioeconomy. To live in abundance beyond the next millennium using the ability of living things, CHITOSE pursues the possibilities of biotechnology through technological and business development collaborating with its business partners all over the world. About CHITOSE BIO EVOLUTION PTE. LTD. (head office that oversees entire Group) Established in October, 2011 Head Office located in Singapore CEO: Tomohiro FUJITA, Ph. D. About CHITOSE Laboratory Corp. (responsible for the project) Established in November, 2002 Head Office located in Kanagawa Prefecture, Japan CEO: Tomohiro FUJITA, Ph. D. COO: Rie KUGIMIYA Our Projects, ▼Breaking away from dependence on fossil resources! Project to build an algae industry JP: https://matsuri.chitose-bio.com/ EN: https://matsuri.chitose-bio.com/en ▼Project to speed up and to implement lower the cost of the biopharmaceutical manufacturing process JP: https://chitose-bio.com/cld-service EN: https://chitose-bio.com/jp/cld-service ▼Providing tasty crops for a thousand years to come! Project to promote agriculture that emphasizes a healthy soil environment JP: https://agriculture.chitose-bio.com/en EN：https://agriculture.chitose-bio.com/ja

Dioseve Inc. Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost.

The HORIBA Group of worldwide companies provides an extensive array of instruments and systems for applications ranging from automotive R&D, process and environmental monitoring, in-vitro medical diagnostics, semiconductor manufacturing and metrology, to a broad range of scientific R&D and QC measurements. Proven quality and trustworthy performance have established widespread confidence in the HORIBA Brand.

Integriculture Inc., a cellular agriculture platform company, develops sustainable protein, namely cell-based meat, and offers its production capability and technology to variety of clients wanting to develop products involving cell culture. Cell-based meat carries high hope as the holy grail to sustainable protein, for which $2T market is at stake. However, the production cost has been prohibitively high. Our patented “CulNet System” cultures cells 4~5 orders of magnitude less expensive to enable us to market cell-based meat at competitive prices. The system requires no externally added growth factors or serum, making it cleaner and safer compared to conventional meat, and even products by other cellular agriculture companies. The system in principle cultures any cells and produce anything produced by living things. Its astounding versatility makes it ideal for a general platform for clients wanting to produce food, cosmetics, supplements, functional ingredients, pharmaceuticals, and any other biological and agricultural products.

Japan Blood Products Organization is a medical device company that is involved in the collection and supply of blood for use in transfusions. They are also engaged in research and development of blood products.

Medmain Inc. is a company to develop and provide "PidPort", a pathological AI analysis solution, with a corporate mission of "to create a world where medical services can be accessed with technology anywhere, anytime." "PidPort" is a product that enables the presentation of highly accurate and rapid analysis results by pathology AI developed by deep learning and the online pathological diagnosis such as remote pathological diagnosis. There is a worldwide shortage of "pathologists" who make diagnoses of patients by looking at their tissues and cells to determine whether there is cancer or not and decide the treatment plan, and this has led to serious delays in pathological diagnosis and large regional disparities. With our product "PidPort", we aim to solve this problem and create a world in which patients can receive a high-quality pathological diagnosis immediately wherever they are.

Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery "NxWave" platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

OncoTherapy Science, Inc. provides pharmaceutical companies with yielded drug candidates by using outcomes obtained from joint research with universities and companies. These outcomes include oncogene information isolated by comprehensive analysis of genes specifically expressed in cancer cells and functional analysis information of proteins produced by oncogenes and other gene products. We have also been performing research and development business regarding medications.

REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.

RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets. About aiProtein® RevolKa innovatively integrated directed protein evolution with the transformative digital technology, artificial intelligence (AI) to create a proprietary powerful protein engineering technology, called aiProtein®. aiProtein® remarkably accelerates directed protein evolution and enables to create unprecedented engineered proteins. This platform is a robust solution for biologics engineering, for example, to address issues in developability and manufacturability of therapeutic antibodies. aiProtein® enables multi-dimensional simultaneous engineering for protein properties, such as efficacy, affinity, physicochemical properties, immunogenicity, species cross-reactivity, and so on.

ROHTO Pharmaceutical Co., Ltd is a multinational company with a history of over 120 years, renowned for its fast-moving consumer goods and OTC drugs. Headquartered in Osaka, Japan, with various domestic and overseas subsidiaries. Although we were initially known for OTC drugs, part of our DNA is to do the unexpected, and for the purpose of people and society’s well-being, we pursue businesses not limited to pharmaceutical operations. Our devotion to meet and exceed customer expectations is the core of Rohto’s business, which has been our main motivator and guidance throughout these years. Recently we announced our comprehensive Management Vision 2030, establishing the core areas we want to strengthen by 2030. With our spirit of "NEVER SAY NEVER" we strive to make every individual and society healthier. To accomplish this, we are seeking people who can support and accelerate the growth of Rohto. The driving force behind Rohto is unquestionably the “people”. A truly diverse workforce is inherently stronger as it is highlighted by people from varying backgrounds with unique experiences, points of view, and knowledge. We believe that this plays an important role in maximizing creativity and accelerating innovation. Our way of working is by embracing the spirit of close cooperation, taking challenges, stir passionate debate and being action oriented. A career at Rohto will help you realize your potential and push yourself to be the better version of you. Are you ready to take part in this journey?

Established in September 2007, Spiber is a biotech venture company based in Yamagata, Japan. We are dedicated to creating groundbreaking solutions that contribute to sustainable well-being. Driven by an unwavering commitment to building a world where everyone thrives, we develop innovative structural protein solutions, such as the Brewed Protein™ platform, a new material solution inspired by nature's diversity and circularity. By harnessing the power of precision fermentation, Spiber engineers proteins at the molecular level, resulting in versatile materials that can be tailored to specific needs. This innovative solution opens up new possibilities for sustainable and high-performance materials in various industries, including apparel, food, automotive, and more. We and our partners are constantly exploring diverse new applications for Brewed Protein™ materials in order to help pave the way for a brighter future. Our passion lies in fostering a circular economy, minimizing our environmental impact, and working together to build a world that is inclusive, fair, and regenerative. Brewed Protein™ fibers are now commercially available worldwide. Spiber's first mass production plant for protein polymer, located in Thailand, began operations in 2022. As production scales up, our distribution network is expanding to include brands, spinning companies, textile manufacturers, and fiber trading companies.

Teijin is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan's first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Through our purpose of "Pioneering Solutions Togeher for a Healthy Planet". Teijin relentlessly strives to aims to be a company that supports the society of the future by protecting the global environment and addressing the needs of people and communities. Teijin posted consolidated sales of JPY 1,032.8 billion (USD 6.6 billion) and total assets of JPY 1,251.0 billion (USD 8.0 billion) in the fiscal year ending March 31, 2024.

The Separation and Purification group of Tosoh Bioscience, a division of Tosoh Corporation, is a major global supplier of chromatographic solutions predominately serving the pharmaceutical, biotechnology, and chemical industries. Since 1987, our product portfolio has expanded and evolved to anticipate industry demands and exceed our customers' needs. Our comprehensive line of analytical HPLC columns, bulk process media resins, and dedicated GPC systems for polymer analysis, coupled with our expertise, make the solution to your separation and purification process clear. Tosoh Corporation, headquartered in Tokyo, Japan, is the parent of a global chemical and specialty materials group. All instruments, columns, and media sold by the Tosoh Bioscience Separations & Purification group are manufactured at Tosoh's Nanyo Complex in Yamaguchi, Japan. Tosoh Bioscience Separations & Purification Group Facilities: • Tosoh Corporation, Bioscience Division – Japan • Tosoh Bioscience LLC – North and South America • Tosoh Bioscience GmbH – Europe, Middle East, Africa • Tosoh Bioscience Shanghai Co., Ltd. – China • Tosoh Asia, Pte. Ltd. – Southeast Asia • Tosoh India Pvt. Ltd. – India

Nisshin is a Japan-based food processing company that produces and supplies wheat flour, mixed feeds, and pet foods for individuals and pet owners.